Analysis of the association between the use of oral progesterone drugs in early pregnancy and gestational diabetes mellitus
- VernacularTitle:妊娠早期使用口服孕激素类药物与妊娠期糖尿病的关联性分析
- Author:
Yan QIN
1
;
Jinhua GU
2
;
Jing ZHU
3
;
Lin LUO
4
;
Peng PING
5
;
Lingqi GU
1
Author Information
1. Dept. of Pharmacy，the Affiliated Maternal and Child Health Hospital of Nantong University，Jiangsu Nantong 226018，China;School of Pharmacy，Nantong University，Jiangsu Nantong 226001，China
2. Dept. of Pharmacy，the Affiliated Maternal and Child Health Hospital of Nantong University，Jiangsu Nantong 226018，China;School of Pharmacy，Nantong University，Jiangsu Nantong 226001，China;Nantong Institute of Genetics and Reproductive Medicine，Jiangsu Nantong 226007，China
3. Dept. of Obstetrics，the Affiliated Maternal and Child Health Hospital of Nantong University，Jiangsu Nantong 226018，China
4. School of Pharmacy，Nantong University，Jiangsu Nantong 226001，China
5. School of Information Science and Technology，Nantong University，Jiangsu Nantong 226001，China
- Publication Type:Journal Article
- Keywords:
progesterone drugs;
gestational diabetes mellitus;
cohort study;
real-world study;
rational drug use
- From:
China Pharmacy
2025;36(6):721-726
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the association between the use of oral progesterone drugs in early pregnancy and gestational diabetes mellitus （GDM）. METHODS Through real-world retrospective cohort research method， pregnant women who underwent the oral glucose tolerance test （OGTT） at the Affiliated Maternal and Child Health Hospital of Nantong University between January 2022 and January 2023 were enrolled. Based on whether oral progesterone drugs were used in early pregnancy， they were divided into treatment group and control group； propensity score matching （PSM） with a 1∶1 ratio was employed to control for confounding factors； Logistic regression and linear regression were employed to analyze the association between drug factors （whether use of oral progesterone drug， duration of medication， dosage， and drug type） and outcome indicators （occurrence of GDM， fasting blood glucose levels， and OGTT 1 and 2 h blood glucose levels in late pregnancy）. RESULTS A total of 709 pregnant women were enrolled in the two groups before PSM； after PSM， 256 cases were included in both the treatment group and the control group. The results of association analysis indicated that there was no significant association between the use of oral progesterone drugs and GDM （P＞0.05）； but a significant correlation was found with OGTT 1 h blood glucose levels [β＝0.965， 95%CI （0.007，1.922）， P＜0.05]， specifically with Dydrogesterone tablets [β＝0.977， 95%CI （0.009， 1.944）， P＜0.05] and Progesterone soft capsules [β ＝1.089， 95%CI （0.077， 2.102）， P＜0.05]. There was no significant correlation between other drug factors and outcome indicators （P＞0.05）. CONCLUSIONS The use of oral progestogen drugs in early pregnancy is not significantly associated with GDM. The blood glucose levels in late pregnancy， especially OGTT 1 h blood glucose levels， have a certain correlation with Progesterone soft capsules and Dydrogesterone tablets.
